



## NEWS RELEASE

# Coya Therapeutics to Participate in Upcoming Investor Relations and Clinical Trials Conferences

2025-11-25

HOUSTON--(BUSINESS WIRE)-- Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative disorders, announces the company's management team will participate in two upcoming conferences.

## 8th Annual Evercore Healthcare Conference

---

Date: December 2, 2025  
Time: 8:45-9:05 am ET  
Format: Fireside Chat  
Participant: Dr. Arun Swaminathan, Ph.D., Chief Executive Officer  
Location: Miami, FL  
Webcast: <https://wsw.com/webcast/evercore52/coya/2359192>

Coya's management team will be available for one-on-one meetings during the Evercore Conference for interested parties.

## 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference

---

Date: December 2, 2025  
Time: 3:10-3:50 pm ET  
Format: Roundtable Discussion Titled "Charting the Path Forward for Combination Therapy in Alzheimer's Disease: Challenges, Considerations, and

Collaborative Solutions"  
Participant: Dr. Fred Grossman, D.O., FAPA, President and Chief Medical Officer  
Location: Sapphire Ballroom, Level 4, Hilton San Diego Bayfront, San Diego, CA

Additional details about the panel can be found here: <https://www.ctad-alzheimer.com/program>.

The live and archived webcast(s) will be accessible from the Company's website at <https://coyatherapeutics.com/> under the Investor Relations section - Events and Presentations. The replay of the webcast will be accessible for 90 days.

## About Coya Therapeutics, Inc.

Headquartered in Houston, TX, Coya Therapeutics, Inc. (Nasdaq: COYA) is a clinical-stage biotechnology company developing proprietary treatments focused on the biology and potential therapeutic advantages of regulatory T cells ("Tregs") to target systemic inflammation and neuroinflammation. Dysfunctional Tregs underlie numerous conditions, including neurodegenerative, metabolic, and autoimmune diseases. This cellular dysfunction may lead to sustained inflammation and oxidative stress resulting in lack of homeostasis of the immune system.

Coya's investigational product candidate pipeline leverages multiple therapeutic modalities aimed at restoring the anti-inflammatory and immunomodulatory functions of Tregs. Coya's therapeutic platforms include Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.

For more information about Coya, please visit [www.coyatherapeutics.com](http://www.coyatherapeutics.com).

## Forward-Looking Statements

This press release contains "forward-looking" statements that are based on our management's beliefs and assumptions and on information currently available to management. Forward-looking statements include all statements other than statements of historical fact contained in this presentation, including information concerning our current and future financial performance, business plans and objectives, current and future clinical and preclinical development activities, timing and success of our ongoing and planned clinical trials and related data, the timing of announcements, updates and results of our clinical trials and related data, our ability to obtain and maintain regulatory approval, the potential therapeutic benefits and economic value of our product candidates, competitive position, industry environment and potential market opportunities. The words "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," and similar expressions are intended to identify forward-looking statements.

Forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other factors including, but not limited to, those related to risks associated with the impact of COVID-19; the success, cost and

timing of our product candidate development activities and ongoing and planned clinical trials; our plans to develop and commercialize targeted therapeutics; the progress of patient enrollment and dosing in our preclinical or clinical trials; the ability of our product candidates to achieve applicable endpoints in the clinical trials; the safety profile of our product candidates; the potential for data from our clinical trials to support a marketing application, as well as the timing of these events; our ability to obtain funding for our operations; development and commercialization of our product candidates; the timing of and our ability to obtain and maintain regulatory approvals; the rate and degree of market acceptance and clinical utility of our product candidates; the size and growth potential of the markets for our product candidates, and our ability to serve those markets; our commercialization, marketing and manufacturing capabilities and strategy; future agreements with third parties in connection with the commercialization of our product candidates; our expectations regarding our ability to obtain and maintain intellectual property protection; our dependence on third party manufacturers; the success of competing therapies or products that are or may become available; our ability to attract and retain key scientific or management personnel; our ability to identify additional product candidates with significant commercial potential consistent with our commercial objectives; and our estimates regarding expenses, future revenue, capital requirements and needs for additional financing.

We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives, and financial needs. Moreover, we operate in a very competitive and rapidly changing environment, and new risks may emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed herein may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Although our management believes that the expectations reflected in our forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances described in the forward-looking statements will be achieved or occur. We undertake no obligation to publicly update any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

### Investor Contact

David Snyder, CFO

[david@coyatherapeutics.com](mailto:david@coyatherapeutics.com)

astr partners

Matthew Beck

**matthew.beck@astrpartners.com**

917-415-1750

### Media Contacts

Russo Partners

Olipriya Das

**Olipriya.Das@russopartnersllc.com**

646-942-5588

Source: Coya Therapeutics, Inc.